Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients

Georgia McDonald, …, Terry Butters, Elizabeth C. Jury


Patients with the autoimmune rheumatic disease systemic lupus erythematosus (SLE) have multiple defects in lymphocyte signaling and function that contribute to disease pathogenesis. Such defects could be attributed to alterations in metabolic processes, including abnormal control of lipid biosynthesis pathways. Here, we reveal that CD4+ T cells from SLE patients displayed an altered profile of lipid raft–associated glycosphingolipids (GSLs) compared with that of healthy controls. In particular, lactosylceramide, globotriaosylceramide (Gb3), and monosialotetrahexosylganglioside (GM1) levels were markedly increased. Elevated GSLs in SLE patients were associated with increased expression of liver X receptor β (LXRβ), a nuclear receptor that controls cellular lipid metabolism and trafficking and influences acquired immune responses. Stimulation of CD4+ T cells isolated from healthy donors with synthetic and endogenous LXR agonists promoted GSL expression, which was blocked by an LXR antagonist. Increased GSL expression in CD4+ T cells was associated with intracellular accumulation and accelerated trafficking of GSL, reminiscent of cells from patients with glycolipid storage diseases. Inhibition of GSL biosynthesis in vitro with a clinically approved inhibitor (N-butyldeoxynojirimycin) normalized GSL metabolism, corrected CD4+ T cell signaling and functional defects, and decreased anti-dsDNA antibody production by autologous B cells in SLE patients. Our data demonstrate that lipid metabolism defects contribute to SLE pathogenesis and suggest that targeting GSL biosynthesis restores T cell function in SLE.
Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients

Georgia McDonald,1 Shantal Deepak,1 Laura Miguel,1 Cleo J. Hall,1 David A. Isenberg,1 Anthony I. Magee,2 Terry Butters,3 and Elizabeth C. Jury1

1Centre for Rheumatology Research, Department of Medicine, University College London, Rayne Building, London, United Kingdom.
2Section of Molecular Medicine, National Heart and Lung Institute, Imperial College London, South Kensington, London, United Kingdom.
3Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom.

Patients with the autoimmune rheumatic disease systemic lupus erythematosus (SLE) have multiple defects in lymphocyte signaling and function that contribute to disease pathogenesis. Such defects could be attributed to alterations in metabolic processes, including abnormal control of lipid biosynthesis pathways. Here, we reveal that CD4+ T cells from SLE patients displayed an altered profile of lipid raft–associated glycosphingolipids (GSLs) compared with that of healthy controls. In particular, lactosylceramide, globotriaosylceramide (Gb3), and monosialotetrahexosylganglioside (GM1) levels were markedly increased. Elevated GSLs in SLE patients were associated with increased expression of liver X receptor β (LXRβ), a nuclear receptor that controls cellular lipid metabolism and trafficking and influences acquired immune responses. Stimulation of CD4+ T cells isolated from healthy donors with synthetic and endogenous LXR agonists promoted GSL expression, which was blocked by an LXR antagonist. Increased GSL expression in CD4+ T cells was associated with intracellular accumulation and accelerated trafficking of GSL, reminiscent of cells from patients with glycolipid storage diseases. Inhibition of GSL biosynthesis in vitro with a clinically approved inhibitor (N-butyldeoxynojirimycin) normalized GSL metabolism, corrected CD4+ T cell signaling and functional defects, and decreased anti-dsDNA antibody production by autologous B cells in SLE patients. Our data demonstrate that lipid metabolism defects contribute to SLE pathogenesis and suggest that targeting GSL biosynthesis restores T cell function in SLE.

Introduction

The mechanisms underlying the immunopathogenesis of the autoimmune rheumatic disease systemic lupus erythematosus (SLE) remain uncertain; however, both the disease and its treatment result in a substantially increased risk of cardiovascular disease, suggesting that a defect in lipid metabolism contributes to the disease process (1). In support of this concept, patients are characterized by dyslipidemia and defects in lymphocyte plasma membrane lipid rafts that result in increased cell stimulation (2, 3).

Glycosphingolipids (GSLs) are essential for many cellular processes and are composed of a ceramide backbone embedded in the outer leaflet of the plasma membrane and a sugar moiety that projects into the extracellular space (4). GSLs are enriched predominantly in lipid rafts, regions in the plasma membrane that coordinate the interaction of key signaling molecules that facilitate lymphocyte activation and function (2, 5). Furthermore, differential GSL expression influences a range of T cell functions including TCR-mediated signaling (6–8), apoptosis (9), and recycling and endocytosis of membrane signaling and receptor molecules (4).

The control of plasma membrane GSL levels is tightly regulated. De novo biosynthesis is catalyzed by enzymes that promote sequential molecular changes from ceramide to generate unique GSL categories including globo-, asialo-, and a-series GSLs (Figure 1A and ref. 10). Vesicular trafficking of newly synthesized lipids to the plasma membrane and subsequent lysosomal and/or late endosomal degradation are also integral to the maintenance of healthy GSL levels (11). Alterations to these processes can lead to a plethora of clinical manifestations, including the lysosomal storage diseases (LSDs) Niemann-Pick type C (NPC), Fabry disease, and Gaucher disease (12). However, very little is known about the effect of altered GSL expression on T cell function in human health and autoimmunity.

CD4+ T cells from SLE patients are characterized by many abnormalities including: increased levels of raft-associated GSLs and cholesterol; defects in the lipid raft location and function of key TCR signaling molecules; accelerated recycling of TCR-associated proteins; and increased cell death and defects in mitochondrial function and autophagy (2, 3, 13). Given that GSLs mediate many of these cellular processes (4, 12), it is possible that changes in GSL expression could contribute to SLE pathogenesis. Intriguingly, manipulation of membrane lipids by in vitro culture with atorvastatin (known to reduce cholesterol biosynthesis) can normalize membrane GM1 expression, phosphorylation of LCK and ERK, and production of IL-10 and IL-6 in T cells from SLE patients (14). This effect suggests that targeting membrane lipids could control or alter immune cell activation and may be an important therapeutic approach for autoimmune disease.

Here, we show that CD4+ T cells from SLE patients had a disrupted GSL profile that was associated with accelerated GSL trafficking and accumulation in intracellular compartments. We found that elevated GSL expression could be recapitulated in healthy T cells by in vitro stimulation with synthetic (GW3965) or potential endogenous liver X receptor β (LXRβ) agonists (oxidized LDL and serum), suggesting that T cell defects in SLE patients could be driven, in part, by dyslipidemia. Inhibition of GSL expression in vitro using the clinically approved inhibitor N-butyldeoxy- nojirimycin (NB-DNJ) (15) modified GSL metabolism and T cell...
function to resemble that observed in T cells from healthy donors. Thus, our findings suggest that defects in lipid metabolism contribute to the immunopathogenesis of SLE and that targeting lipid biosynthesis pathways could be a novel therapeutic strategy for the treatment of SLE.

Results

Dysregulated GSL expression in CD4+ T cells from patients with SLE. Our recent findings show that changes in the composition and organization of lipids in the plasma membrane can influence T cell function (16).
ids were extracted from negatively isolated CD4+ T cells from SLE patients and healthy donors and analyzed by HPLC (ref. 17 and Figure 1B). Quantitative analysis of the HPLC plots revealed (18) that T cells from SLE patients had a profoundly altered GSL profile, with a significantly increased expression of lactosylceramide (LC), GA2, Gb3, GM2, GD1a, and GM1 compared with that of T cells from healthy donors (Figure 1C). This represented an increase in several different GSL species (including globo-, α-, and asio-lo-series) when assessed according to their position in the GSL biosynthesis pathway (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI69571DS1).

We determined GSL expression in CD4+ T cell plasma membranes by flow cytometry using the available GSL-specific antibodies. We found that expression of LC, Gb3 (using anti-CD77 antibody but also binding to Shiga toxin B; data not shown), and GM1 (binding to cholera toxin B [CTB]) was substantially increased in CD4+ T cells from SLE patients compared with that in cells from healthy donors and from patients with other autoimmune disease (OAD) (Figure 1, D–F). We observed no change in the expression of GM3 or GM2 (data not shown). Culture of T cells from healthy donors with a potent inhibitor of GSL synthesis (D-PDMP) decreased cell-surface GSL expression, confirming specificity of the anti-GSL antibodies (Supplemental Figure 1B).

Interestingly, we found that expression of GM1 was low in all samples, as measured by HPLC, compared with its detection by CTB binding and flow cytometry. This has been observed previously and is attributed to CTB binding to related structures including GM3 and GM2 (T. Butters, unpublished observations and ref. 19). In light of this finding, we continued to use CTB binding as a surrogate marker of GSL expression rather than a specific marker for GM1. GSL expression was not influenced by disease activity, as assessed by the British Isles Lupus Assessment Group (BILAG) global score (Supplemental Figure 1C), or by treatment with prednisolone or hydroxychloroquine (Supplemental Figure 1, D and E). Since hydroxychloroquine is known to affect lipid homeostasis (20), we cultured healthy T cells with this drug for 72 hours at a concentration equivalent to that detected in vivo, but did not observe an effect on plasma membrane LC, CTB, or Gb3 expression (Supplemental Figure 1F).

Thus, we show that GSL expression in both total cellular and plasma membrane compartments was profoundly altered in ex
vivo CD4+ T cells from patients with SLE compared with that seen in healthy donors and disease controls.

*Increased GSL expression is associated with defective GSL homeostasis in T cells from SLE patients.* Increased GSL expression is associated with T cell activation (2, 21). We confirmed this observation in T cells from healthy donors; however, an analysis of GSL expression in functional CD4+ T cell subsets revealed that increased GSL expression was not restricted to activated T cells in SLE patients (Supplemental Figure 2, A–E). The association between cell activation and increased GSL expression was further confirmed when we either rested (no stimulation) or TCR stimulated CD4+ T cells in vitro. In contrast to our observation that T cells from healthy donors upregulated CTB binding and LC and Gb3 expression in response to TCR stimulation, T cells from patients with SLE had a dysregulated pattern of GSL expression in both resting and TCR-activated cells (Supplemental Figure 2F). Further, we detected no evident changes in GM3 expression levels (data not shown). Together, these results suggest that T cell activation was not solely responsible for the increased GSL expression we observed in patients.

GSL expression can be driven by mechanisms other than TCR stimulation. GSLs are derived from ceramide (Figure 1A), whose production is mediated by proinflammatory cytokines and an altered serum lipid environment, among other stimuli (22). We tested whether these stimuli translated into increased GSL expression in CD4+ T cells from healthy donors by stimulating cells with TNF-α and IL-6, which are significantly increased in the serum of SLE patients (Supplemental Figure 3A and ref. 1), or with synthetic agonists of nuclear receptors that regulate cellular lipid homeostasis, such as liver X receptor (LXR) (GW3965) and PPARγ (23). Surprisingly, we found that stimulation with recombinant human TNF-α, IL-6, and PPARγ agonist had an insignificant effect on GSL expression (Supplemental Figure 3B and data not shown). In contrast, GW3965 stimulation significantly increased LC expression and CTB binding in CD4+ T cells from healthy donors after a 24-hour culture (Figure 2, A–C). We found that this effect was transient, with LC expression and CTB binding returning to ex vivo levels by 72 hours, suggesting that GSL expression was strictly controlled. In contrast, CD4+ T cells from SLE patients displayed a sustained increased expression of GSL after GW3965 stimulation for 72 hours (Figure 2, A–C).

A role for LXR in defective CD4+ T cell GSL homeostasis was supported by our finding that LXRβ and its target genes NPC1 and NPC2, but not ABCAI or ABCG1, were upregulated in ex vivo CD4+ T cells from SLE patients compared with those from healthy donors, as assessed by quantitative PCR (qPCR) (Figure 2D). We found that SREBP2, a gene that can indirectly affect LXR expression

Figure 3
Upregulation of LXRβ by oxysterol and TCR stimulation. (A) CD4+ T cells from 3 healthy donors and 3 SLE patients were cultured for 18 hours with GW3965 or CM and analyzed by Western blotting for LXRβ expression. (B) Cumulative data. Paired and 2-tailed Student's t test; *P ≤ 0.05. (C) CD4+ T cells from 5 healthy donors and 5 SLE patients cultured for 18 hours with GW3965 or CM were assessed by qPCR for LXRβ expression. Cumulative results comparing LXRβ with GAPDH control. Paired and 2-tailed Student's t tests; *P ≤ 0.05. PBMCs from a healthy donor were cultured for 72 hours (all plus IL-2) with serum from 5 heterologous healthy donors (HC serum), 5 SLE patients (SLE serum), or with CM only (MO). (D) Cumulative data. One-way ANOVA; *P = 0.05. (E) CD4+ T cells from 5 healthy donors were cultured for 72 hours with LDL, oxidized LDL (oxLDL), or CM before CTB staining. Representative histograms and cumulative data. One-way ANOVA; *P ≤ 0.01. (F) PBMCs from a healthy donor were cultured with serum from 12 healthy donors, 12 SLE patients, or with CM (all plus IL-2) (for 72 hours and for 10 days) and stained with CTB. Cumulative data showing percentage change from CM. One-way ANOVA; *P ≤ 0.05. (G) PBMCs from 4 SLE patients and 4 healthy donors were cultured for 3 days with GW3965 ± the LXR antagonist 5CPPSS-50 and stained with CTB. One-way ANOVA; *P ≤ 0.05. (H) PBMCs from a healthy donor were cultured for 10 days as described in F with serum from 4 SLE patients ± 5CPPSS-50 and stained with CTB. One-way ANOVA; *P = 0.03.
LXRβ expression in CD4+ T cells is upregulated by oxysterol and TCR stimulation. Most work examining the function of LXRβ has been described in macrophages, where it is known to be stimulated by increased cellular or serum oxysterols (25). To ascertain whether this was also the case in CD4+ T cells, we stimulated them with the synthetic oxysterol agonist GW3965. GW3965 activation increased LXRβ protein and gene expression levels in T cells from both healthy donors and SLE patients (Figure 3, A–C). This effect was recapitulated by culture with serum from SLE patients (as a potential source of endogenous oxysterols) compared with cells cultured with serum from healthy individuals or with medium alone (Figure 3D). Furthermore, we observed that culture with oxidized LDL or extended culture with serum from SLE patients increased GSL expression in CD4+ T cells from healthy donors (Figure 3, E and F). This suggests that chronic stimulation by potential endogenous LXR agonists in the serum of SLE patients could contribute to increased T cell GSL biosynthesis.

TCR stimulation also increases GSL expression (refs. 2, 21, and Supplemental Figure 2F), and we found that in vitro TCR stimulation significantly upregulated LXRβ gene and protein expression in both healthy and SLE patients (Supplemental Figure 3, C and D, and data not shown).

Finally, to confirm that oxysterol and TCR stimulation of LXRβ influenced GSL expression, we costimulated CD4+ T cells from SLE patients and healthy donors with an LXR antagonist (5-chloro-N-2′-n-pentylphenyl-1,3-dithiophthalimide, 5CPPSS-50) (2, 26). 5CPPSS-50 blocked LXRβ upregulation in response to GW3965 and SLE serum (Supplemental Figure 3, E and F), but had only an insignificant effect following TCR stimulation (data not shown). Similarly, 5CPPSS-50 reversed increased GSL expression in response to GW3965 and SLE serum, but not TCR stimulation (Figure 3, G and H, and data not shown).

Together, these results support the hypothesis that increased GSL expression in T cells from SLE patients is driven, in part, by
LXRβ stimulation via altered serum lipids and T cell activation. They also suggest that the homeostatic mechanisms controlling balanced GSL expression levels were dysregulated in CD4+ T cells from SLE patients, resulting in an accumulation of cellular GSL.

**GSL recycling and turnover is altered in T cells from SLE patients compared with those from healthy controls.** Stimulation of LXR is known to directly control expression of NPC1 and NPC2 proteins, which regulate cellular GSL transport and recycling (27). Since expression of these genes was also increased in CD4+ T cells from patients with SLE (Figure 2D), we investigated whether abnormal GSL trafficking contributed to their increased surface expression in SLE patients. We used a fluorescently labeled exogenous probe, Bodipy-LC, which emits fluorescence at differential wavelengths depending on its cellular location (520–560 nm [green] when incorporated into the plasma membrane and cytosol or >590 nm [red] when concentrated into intracellular compartments including endosomes or lysosomes) (28). At baseline, T cells from SLE patients had incorporated significantly more Bodipy-LC into both the plasma membrane and cytosol (green fluorescence) and intracellular compartments (red fluorescence) compared with healthy controls (1-minute time point Figure 4A, left panels, and Figure 4B). After 30 minutes, T cells from SLE patients retained higher levels of Bodipy-LC, whereas these levels were significantly reduced in T cells from healthy controls (Figure 4A, right panels).

**Figure 5**
Increased LAMP1 expression and altered lipid colocalization to functionally normal lysosomes in SLE CD4+ T cells. (A) PBMCs from 11 healthy donors and 11 SLE patients were surface stained for CD4-APC before fixing, permeabilizing, and staining for intracellular LAMP1-PE (CD107a-PE). Representative dot plots and cumulative data. Two-tailed Student’s t test; ****P = 0.0001. (B–E) CD4+ T cells from 6 SLE patients and 3 healthy donors were fixed and permeabilized before staining for LAMP1 and either CTB (B) or LC (D) and analyzed by confocal microscopy. Scale bars: 5 μM (insets show >2.5 enlargement). Colocalization of LAMP1-CTB (C) or LAMP1-LC (E) assessed by Pearson’s colocalization coefficient (Rr). Cumulative data. Two-tailed Student’s t test, *P = 0.05. (F) PBMCs from 10 SLE patients were labeled with CD4-APC and incubated with LysoSensor Green DND before flow cytometric analysis. Results were correlated with LAMP1 expression measured in F. R² = 0.4754; *P ≤ 0.05.
els, and Figure 4B). Although T cells from SLE patients incorporated and retained significantly more Bodipy-LC than those from healthy donors, the rate of reduction of this probe in the plasma membrane, cytosol, and intracellular compartments was comparable over time (Supplemental Figure 4A).

We found that the uptake of Bodipy-LC was an active process, since inhibition of clathrin-independent endocytosis (known to be responsible for GSL internalization; ref. 28) using the dynamin inhibitor dynasore or the Src kinase inhibitor PP2 inhibited the probe’s uptake and reduced its incorporation into intracellular compartments (Figure 4C and data not shown, respectively).

We next investigated both the internalization of endogenous GSLs from the plasma membrane into intracellular compartments and their recycling from intracellular compartments back to the plasma membrane. We observed that GSL internalization was prompt in CD4+ T cells from both healthy donors and SLE patients. However, we found that GSL internalization was significantly more rapid at the 3- and 5-minute time points in T cells from SLE patients compared with those from healthy donors (Figure 4D and data not shown for LC).

Recycling of GSLs back to the plasma membrane was also rapid in T cells from both SLE patients and healthy donors. However, we observed that GSL recycling was more sustained over a 15-minute time course in T cells from SLE patients than in those from healthy donors in whom GSL recycling declined over time (Figure 4E and data not shown for LC).

Thus, elevated cellular GSL levels were associated with accelerated and sustained GSL internalization and recycling dynamics in CD4+ T cells from SLE patients, leading to a net increase in plasma membrane expression.

Increased retention of cellular GSLs in CD4+ T cells from SLE patients. Since cellular GSL expression levels are controlled by lysosomal and/or late endosomal degradation (11), we investigated whether GSL degradation was also defective in T cells from SLE patients compared with those from healthy donors. First, we observed that the expression of the lysosomal marker lysosomal-associated membrane protein 1 (LAMP1) was significantly increased in T cells from SLE patients compared with those from controls (Figure 5A).

We confirmed by confocal microscopy that expression of LAMP1, LC, and CTB binding was elevated in T cells from SLE patients (Figure 5, B and D). We observed that CTB distribution was more clustered in T cells from patients compared with those from healthy and mirrored the pattern of LAMP1 distribution. This was associated with increased CTB and LAMP1 colocalization in SLE patients compared with that observed in healthy donors (Figure 5, B and C). We detected no differences in LC or LAMP1 colocalization (Figure 5, D and E); however, the overall levels of colocalization between GSLs and LAMP1 were low in the T cells from both healthy donors and SLE patients (Figure 5, C and E). On close examination, the distribution pattern for GSLs and LAMP1 suggested subcompartmentalization of the lysosomes between protein-rich (LAMP1) and lipid-rich (CTB/LC) regions (Figure 5, B and D, enlarged insets).
Figure 7

NB-DNJ modifies TCR-associated defects in T cells from patients with SLE. PBMCs from 5 SLE patients and 5 healthy donors were cultured for 7 days with NB-DNJ. Cells were labeled with anti-CD3/CD28 (1 μg/ml) and cross-linking anti-mouse IgG on ice before culturing at 37°C for 1 and 5 minutes. Cells were fixed and labeled with fluorescent barcoding reagents and stained for CD4-APC and intracellularly stained for the phosphorylated signaling proteins pTCR-ζ, pERK, pAKT, and pNF-κB. (A) Cumulative results from three separate experiments. Two-tailed Student’s t-test; *P ≤ 0.05 or paired t-test; **P = 0.001. PBMCs from 24 SLE patients and 11 healthy donors were TCR stimulated for 72 hours with anti-CD3/CD28 (1 μg/ml) with or without 10 μM NB-DNJ. Cell culture supernatants were collected. Cells were surface stained with CD4-v450 and intracellularly stained for Ki67-PE and assessed by flow cytometry. (B) Representative flow cytometric dot plots (C) and cumulative results showing Ki67 expression as the percentage change from unstimulated controls. Two-tailed Student’s t-test; *P ≤ 0.05. Cell culture supernatants from 12 SLE patients and 10 healthy donors collected from B were analyzed by CBA. Representative CBA plots (D) and cumulative data (E) are shown. Two-tailed Student’s t-test and paired t-test; *P ≤ 0.05. (F) CD4+ T cells isolated from 4 SLE patients were pretreated with NB-DNJ, then cocultured with autologous B cells for 7 days in the presence of anti-CD3 (1 μg/ml). The production of anti-dsDNA antibodies was detected by ELISA. Paired Student’s t-test; *P ≥ 0.05.
No significant differences were noted in early endosome antigen 1 expression or colocalization with LC or CTB in T cells from healthy donors and SLE patients (Supplemental Figure 4, B–D).

We tested whether lysosomes in T cells from SLE patients were defective and unable to process excess levels of intracellular GSLs. Using a probe to detect lysosomal acidity (LysoSensor Green DND-189), we found a significant positive correlation between LAMP1 and LysoSensor staining in T cells from SLE patients, suggesting that although the lysosomes were increased in number, they were functionally normal (in terms of acidity) (Figure 5F).

Therefore, the results imply that the normal mechanisms controlling GSL expression were overwhelmed by increased GSL biosynthesis in T cells from SLE patients. This culminated in accelerated GSL trafficking and the accumulation of GSLs in the plasma membrane and intracellular compartments, despite apparently normal lysosome function.

**Inhibition of GSL biosynthesis reduced GSL expression and trafficking in CD4 T cells from patients with SLE.** GSL accumulation, which interferes with GSL trafficking and lysosomal degradation, is also a feature of patients with LSDs (12). Blocking GSL synthesis using specific inhibitors, including NB-DNJ (a reversible competitive inhibitor of glucosylceramide synthase; ref. 29), rectifies defective GSL homeostasis and is used therapeutically in patients (15). Therefore, we assessed the in vitro effect of NB-DNJ on T cells from SLE patients. Culture for 72 hours in the presence of NB-DNJ diminished TCR-induced upregulation of CTB binding and LC and GB3 expression in T cells from SLE patients to the levels observed in T cells from healthy donors (Figure 6A and data not shown for GB3). This was accompanied by a significantly reduced rate of internalization of endogenous GSL (Figure 6B and data not shown for LC) and reduced uptake of exogenous Bodipy-LC by T cells from SLE patients (Figure 6C). Furthermore, culture with NB-DNJ altered the intracellular distribution of internalized Bodipy-LC in T cells from SLE patients in a pattern that we consistently observed in T cells from healthy donors (Figure 6D) and was associated with a reduced expression of LAMP1 in T cells from SLE patients (Figure 6E).

**NB-DNJ moderated TCR-associated defects in T cells from patients with SLE.** Since culture with NB-DNJ was able to restore a healthy pattern of GSL expression and trafficking in T cells from patients with SLE, we assessed whether it could also reverse some of the in vitro lipid raft–associated defects associated with these T cells (2, 3). We cultured PBMCs with and without NB-DNJ (10 μM) for 7 days to ensure that endogenous GSL levels were reduced. We then stimulated CD4 T cells with anti-CD3/28 antibodies and used flow cytometry to measure the phosphorylation of key signaling molecules. As described previously, signaling molecule phosphorylation patterns are altered in T cells from SLE patients compared with those from healthy donors (2, 3). However, we found that TCR-mediated phosphorylation of TCR-ζ, ERK, and NF-κB was partially restored in NB-DNJ–treated T cells from SLE patients, while we detected no significant effect on AKT phosphorylation (Figure 7A). The gating strategy for the analysis is shown in Supplemental Figure 5, A and B.

As expected, moderation of T cell signaling by NB-DNJ was associated with the partial normalization of some T cell functions. This included reduced proliferation, as measured by Ki67 expression (Figure 7, B and C) and thymidine incorporation (Supplemental Figure 5C), and altered regulation of IL-6, IL-10, and TNF-α production (Figure 7, D and E). In addition, we observed

---

**Figure 8**

Proposed model for altered GSL expression and metabolism in CD4+ T cells from SLE patients. We propose that several components of SLE pathology, including dyslipidemia and T cell hyperactivity (i), elicit upregulation of the nuclear receptor LXRβ, and hence its downstream target genes NPC1 and NPC2 (ii). Enhanced activation of LXRβ induces increased de novo GSL biosynthesis (iii). CD4+ T cells from SLE patients are characterized by accelerated GSL trafficking and accumulation of GSL in the plasma membrane (iv) and intracellular compartments (v), despite higher levels of functionally normal lysosomes (vi). Inhibition of GSL biosynthesis with NB-DNJ reduced cellular GSL levels and modified cell function in CD4+ T cells from SLE patients (vii). TGN, trans-Golgi network.
that apoptosis, as measured by annexin V binding, was reduced (data not shown).

Finally, we found that NB-DNJ reduced the capacity of T cells from SLE patients to drive anti-dsDNA antibody production by autologous B cells (Figure 7F). Thus, we show that NB-DNJ, a successful, clinically approved therapy for LSDs, could rectify some of the defects associated with abnormal T cell function in SLE patients.

Discussion

We report a number of findings in support of our hypothesis that alterations in the control of lipid metabolism underlie abnormal T cell function in patients with SLE. First, we demonstrate a profound alteration in the GSL profile of T cells from SLE patients. Second, we show that defects in GSL biosynthesis were driven, in part, by stimulation of the lipid-responsive nuclear receptor LXRβ. Finally, we reveal that NB-DNJ, a successful, clinically approved therapy for patients with LSDs, normalized GSL expression and rectified some of the signaling and functional abnormalities characteristic of T cells from SLE patients. A scheme outlining the proposed mechanism for altered GSL expression in T cells from SLE patients is shown in Figure 8.

The consequences of GSL accumulation have been studied extensively in experimental models and in patients with LSDs. These diseases result from mutations in single proteins involved in the control of GSL trafficking or metabolism (12). Patients are characterized by severe neurological, renal, and cardiac deficiencies attributed to GSL accumulation in organs and tissues as well as by multiple immunological defects (30). Unlike most of the inherited LSDs, which are characterized by the accumulation of a specific class of GSL, we found that the accumulation of GSLS in CD4+ T cells from SLE patients was not restricted to a specific GSL species and that the precise GSL profile varied between patients. This observation suggests that the increased GSL expression was not associated with a specific defect in synthase enzyme expression or activity. However, although we did not detect any significant change in the expression of key GSL synthase enzymes by Western blot analysis, this does not rule out the possibility of a defect in enzyme activity or in one of the other enzymes that control GSL expression (31).

There is a growing appreciation that GSL heterogeneity contributes to membrane protein compartmentalization in resting and activated T cells. Within T cells, the distribution of GSLS is heterogeneous; for example, GM1 and GM3 are distributed asymmetrically toward the leading edge or the uropod of T cells, respectively (32). The essential proximal TCR signaling molecules LCK and LAT reside in different lipid raft subsets that fuse upon TCR stimulation (33), and the interaction of TCR-associated signaling molecules (including LCK, LFA1, and PI3K) with GM3 or GM1 induces differential recruitment of downstream signaling targets that affect T cell function (34, 35). Moreover, recent reports show that CD4+ and CD8+ T cells exclusively require α-series and β-series GSLS, respectively, for TCR-mediated activation (8, 36). The reduction of cellular GSL levels by pharmacological means or by disruption of GM3 synthase activity can inhibit the differentiation of CD4+ T cells into Th17 cells (7) and reduce cytokine production in activated T cells during viral infection (31).

We also observed accelerated GSL recycling and a substantial accumulation of intracellular GSLS in T cells from SLE patients. A consequence of increased GSL trafficking could be an accelerated recycling of cell surface proteins that affect cell activation (4, 12). Importantly, ex vivo T cells from SLE patients are characterized by increased recycling of TCR-associated molecules, including CD4 and CTLA-4, which affects their activation and inhibitory functions, respectively (37).

Therefore, an altered plasma membrane GSL profile could influence the balance between positive and negative signals transduced during activation and contribute to the characteristic T cell dysfunction seen in SLE patients. This proposition is supported by work showing that in vitro cross-linking of GSLS elicits different functional responses in CD4+ T cells from healthy donors compared with those from SLE patients (E. Jury, unpublished observations). The presence of anti-GSL antibodies in the serum of a small percentage of SLE patients has been reported previously (38). However, anti-GSL antibodies were not detected in our patient cohort (E. Jury, unpublished observations). Nevertheless, it remains uncertain how differential GSL expression alters T cell function in vivo, although it seems likely that GSLS play an essential role in modifying signals transduced via TCR and costimulatory molecule activation.

Our results imply that more than one factor influences increased GSL levels in patients. In addition to TCR stimulation, activation of lipid biosynthesis pathways using an LXR agonist induced a sustained increase in GSL levels in CD4+ T cells from SLE patients, but not in T cells from healthy controls. This was associated with an increased ex vivo expression of LXRβ, but not LXRα, and some LXRβ target genes in T cells from SLE patients. To date, little is known about the interaction between TCR-stimulation and lipid homeostasis. Tontonoz et al. showed that TCR stimulation downregulates some LXRβ target genes involved in cholesterol efflux (39). Crucially, this suggests that the functional capacity of immune cells can be regulated by mechanisms controlling lipid homeostasis (25, 39).

The results of our study point to an unrecognized function for LXRβ stimulation in the control of T cell GSL expression. Contrary to previous reports examining LXRβ expression in macrophages, we found that GW3965 and oxLDL stimulation upregulated LXRβ protein and mRNA expression in human T cells (Figure 3 and ref. 40). Since differences in LXR stimulation exist between human and murine macrophages and between different cell types (41), this upregulation could possibly be due to an unrecognized human T cell–specific LXR enhancer. However, we cannot rule out a role of LXRα in lipid-mediated T cell function, although no difference in ex vivo (Figure 2D) or GW3965-stimulated LXRα expression (data not shown) was found in T cells from healthy donors and SLE patients.

Since levels of cellular cholesterol and GSL are closely associated (12, 42), it seems likely that alterations in cholesterol homeostasis could also contribute to changes in GSL expression in T cells from SLE patients. Two primary features of LSDs are an aberrant trafficking of GSLs coupled with cholesterol accumulation and an inability of lysosomes to degrade excess glycolipids (12). A similar phenotype is observed in T cells from SLE patients, since cholesterol measured by filipin binding is also elevated (2). Interestingly, SREBP2 was upregulated in ex vivo T cells from SLE patients. SREBP2 activates cholesterol synthesis, indirectly activates LXR, and can transactivate NPC1/2 genes (24, 43). Thus, it is clear that more work is needed to fully understand the complex interactions in human T cells that occur between LXRβ, SREBP2, and associated target genes to maintain GSL homeostasis, lipid raft stability, and lipid raft function in health and autoimmunity.

The exact nature of the potential LXR agonists present in the serum or cells of patients needs to be determined. Dyslipidemia is common in SLE patients, and several studies have reported reduced levels of HDL, increased levels of triglycerides, and increased LDL...
oxidation, which can be associated with increased disease activity and proinflammatory cytokine production (1, 44). Thus, it seems likely that defects in GSL expression in SLE patients could be driven by serum dyslipidemia. Indeed, many patients included in the present study had altered lipid levels (Supplemental Table 1).

The ability of inhibitors of GSL biosynthesis to restore defects in lipid (GSL and cholesterol) homeostasis and to inhibit T cell proliferation, cytokine production, and differentiation has been identified previously in cell lines and animal models (7, 45). We found that NB-DNJ treatment of CD4+ T cells from patients with SLE modified their T cell function in response to in vitro TCR stimulation (Figure 7). Critically, this was achieved by reducing GSL levels and modifying GSL recycling and accumulation, effects also seen in cells from patients with LSDs who were treated with GSL reduction therapies (12, 46). Interestingly, we found that NB-DNJ increased TNF-α production in T cells from SLE patients, but decreased its production in T cells from healthy donors. The role of TNF-α in human SLE is controversial; it can cause tissue damage via its proinflammatory activity or be beneficial by dampening autoimmune responses. Such heterogeneity of effect could be due to changes in membrane lipids that influence immune cell function (5). Blocking TNF-α therapeutically has not been accepted in clinical practice (47). There are several precedents for the therapeutic control of lipids, examples of which include HIV infection (48), cancer (49), and atherosclerosis (50). Thus, a growing body of evidence supports the hypothesis that correct cellular lipid metabolism regulates the capacity of T cells to correctly respond to microenvironmental stimuli and that therapeutic targeting of such molecules could influence immune cell activation and help regulate abnormal immune responses in autoimmunity.

In summary, we provide evidence of a profound dysregulation in both cellular and surface GSL expression in CD4+ T cells from SLE patients. This dysregulation was due to increased GSL biosynthesis driven, at least in part, by serum dyslipidemia and T cell hyperactivity in SLE patients. Abnormal GSL levels and a range of functional cellular defects were rectified by targeting GSL biosynthesis with a clinically approved inhibitor. Our findings reveal a role for defects in lipid metabolism in SLE pathogenesis and highlight what we believe to be a novel treatment strategy for the disease.

Methods

Patients and controls
Peripheral blood was obtained from SLE patients attending the lupus clinic at University College Hospital (London, United Kingdom). Suplemental Table 1 provides a summary of the healthy donors included in this study as well as the treatments and clinical characteristics of the SLE patients.

PBMC and CD4+ T cell isolation
PBMCs were isolated from heparinized blood using Ficoll-Paque PLUS (GE Healthcare) gradient centrifugation. PBMCs (10⁶ cells/ml) were resuspended in FCS (Biosera) and 10% DMSO (Sigma-Aldrich) and frozen until use. CD4+ T cells were isolated by negative selection (MACS; Miltenyi Biotec).

Lipid extraction, GSL glycan labeling, and HPLC analysis
Lipids were extracted from CD4+ T cells (10⁶ cells) using chloroform:methanol (v/v). Following ceramide glycanase cleavage of the glycan head groups, glycans were labeled with anthenic acid and analyzed by normal phase HPLC, as previously described (25). The detailed procedure for GSL glycan labeling and HPLC analysis is described in the Supplemental Methods.

tPCR
RNA was extracted from CD4+ T cells with TRIzol (Invitrogen) according to the manufacturer’s instructions. Sample concentration and purity were determined by spectrophotometric analysis. RT-PCR and qPCR were performed using primers for LXRB, NPC1, NPC2, ABCA1, ABCG1, SREBP2, and the housekeeping gene GAPDH (Qiagen).

Cell cultures

T cell activation. PBMCs or CD4+ T cells were cultured in complete medium (CM) (RPMI 1640 containing L-glutamine and NaHCO₃ [Sigma-Aldrich] with 10% FCS [Lonza], and 100 U/μg/ml penicillin-streptomycin [Sigma-Aldrich] at 37°C in 5% CO₂); 1 μg/ml anti-CD3 (HIT-3A); and 1 μg/ml anti-CD28 (CD28.2) (eBioscience). Cells were cultured as above with or without GSL biosynthesis inhibitors (100 μM D-PDMP; Sigma-Aldrich or 10 μM NB-DNJ).

LXR agonist experiments. PBMCs were cultured in CM with or without 1 μM GW3965 (Sigma Aldrich) for 24 hours and 72 hours. Serum experiments. PBMCs were cultured in CM or RPMI and 10% serum from SLE patients or healthy donors plus IL-2 (0.5 ng/ml) for 24 hours, 3 days, 7 days, or 10 days. The CM was replenished every 3 days.

Antagonist experiments. PBMCs or CD4+ T cells were cultured with 1 μM GW3965, anti-CD3/28 (each at 1 μg/ml), or serum from SLE patients or healthy donors with or without an LXR antagonist (10 μM 5C PPSS-50; Wako) for 24 and 72 hours in CM.

T and B cell cocultures. PBMCs were cultured with or without 10 μM NB-DNJ in CM for 24 hours. CD4+ T cells were then negatively isolated and resuspended in CM with autologous B cells negatively isolated from a freshly thawed aliquot. T and B cells were cocultured for 7 days with or without anti-CD3/CD28 (1 μg/ml each) and with or without NB-DNJ (10 μM). Supernatants were removed on day 7 and analyzed by ELISA (Euro Diagnostica) for the presence of anti-IgG dsDNA antibodies.

Flow cytometry
All surface stains were performed in 1% FCS and 0.01% sodium azide in PBS on ice. All data were collected on an LSRII (BD) and analyzed with FlowJo software (Tree Star Inc.).

GSL expression. PBMCs were stained with either CTB-FITC (Sigma-Aldrich), LC-PE-evano dye 5 (Cy5), LC-FITC (LifeSpan Biosciences Inc.), or CD77-FITC (Gh3-FITC), followed by CD4-APC or CD4-BD Horizon V450 (BD Biosciences).

Assessment of K67, LAMP1 (CD107a), and LXRβ expression. Cells were surface stained for 60 minutes before fixation and permeabilization (Fix/Perm Buffer; eBioscience) then stained intracellularly with anti-Ki67–PE (BD Biosciences), washed, and resuspended in LysoSensor Green DND-153 (Molecular Probes) for 30 minutes at 37°C in 5% CO₂.

Measurement of GSL trafficking
Internalization of Bodipy-LC. CD4+ T cells from SLE patients and healthy donors were either labeled ex vivo, cultured overnight in CM with or without 10 μM NB-DNJ, or preincubated with 50 μM dynasore (Invitrogen) or 50 μM Src kinase inhibitor PP2 (Calbiochem). Samples were incubated with 10 μg/ml Bodipy-LC (Invitrogen) on ice for 30 minutes, then at 37°C
for 1 to 30 minutes. Cells were fixed and analyzed by confocal microscopy and flow cytometry. Detailed procedures for Bodipy-LC labeling and detection, internalization of endogenous plasma membrane GSLs, and recycling of endogenous GSLs to the cell surface from intracellular compartments are described in the Supplemental Methods.

**Analysis of cell culture supernatants**

Detection of cytokines from purified CD4+ T cell culture supernatants was performed by cytokine bead array (CBA) analysis (BD Bioscience) according to the manufacturer’s instructions. Samples were analyzed on a FACSAArray Bioanalyzer (BD).

**Quantitative immunoblots**

CD4+ T cells (10^7 cells) were lysed and analyzed by Western blotting using mouse anti-LXRβ (Abcam) or anti-actin mAb (Sigma-Aldrich). Adobe Photoshop was used for quantification of the protein bands (Adobe Systems Inc.).

**Confocal microscopy**

CD4+ T cells were fixed, permeabilized, and blocked before staining for lysosomes (anti-LAMP1 IgG1 and anti-IgG1 Alexa 555), early endosomes (anti-EEA1 IgG and anti-IgG-Alexa 633), and either anti-LC IgM and anti-IgG Alexa Fluor 488 or CTB-FTTC. Detailed microscopy procedures are described in the Supplemental Methods.

**Statistics**

All values are expressed as the absolute mean ± SEM. Analysis for significance was performed with GraphPad Prism software (GraphPad Software) using a 2-tailed Student’s t-test, a paired Student’s t-test, or 1-way ANOVA as specified. P values less than 0.05 were considered significant. Data were tested for normal distribution using the Kolmogorov-Smirnov test with GraphPad Prism software.

**Study approval**

Ethical approval (00/0241, 11/H0808/19) was obtained for this study from the ethics committee of the University College London Hospitals National Service Trust (London, United Kingdom). All participating patients and healthy donors provided written informed consent.

**Acknowledgments**

Arthritis Research UK supports E.C. Jury (18106) and G. McDonald (16067). A University College London Hospital (CRDC) project grant (GCT/2008/EJ) and Lupus UK pilot study award supported L. Miguel. A.I. Magee was supported by MRC grant G0700771. T.D. Butters thanks the Glycobiology Institute of the University of Oxford for support. We thank P. Kabouridis, F. Flores-Borja, and I. Pineda Terra for their critical evaluation of the manuscript.

Received for publication March 15, 2013, and accepted in revised form October 24, 2013.

**Address correspondence to:** Elizabeth Jury, Centre for Rheumatology Research, University College London, Rayne Building, London WC1E 6JF, United Kingdom. Phone: 44.0.20.3108.2154; Fax: 44.0.20.3108.2152; E-mail: ejury@ucl.ac.uk.

---

**References**


